Towards personalized management of ovarian cancer
Algethami, Mashael Kulkarni, Sanat Sadiq, Maaz T Tang, Hiu K C Brownlie, Juliette Jeyapalan, Jennie N Mongan, Nigel P Rakha, Emad A Madhusudan, Srinivasan
Algethami, Mashael
Kulkarni, Sanat
Sadiq, Maaz T
Tang, Hiu K C
Brownlie, Juliette
Jeyapalan, Jennie N
Mongan, Nigel P
Rakha, Emad A
Madhusudan, Srinivasan
Abstract
Despite advances in surgery and chemotherapy, the overall outcomes for patients with advanced ovarian cancer remain poor. Although initial response rates to platinum-based chemotherapy is about 60-80%, most patients will have recurrence and succumb to the disease. However, a DNA repair-directed precision medicine strategy has recently generated real hope in improving survival. The clinical development of PARP inhibitors has transformed lives for many patients with BRCA germline-deficient and/or platinum-sensitive epithelial ovarian cancers. Antiangiogenic agents and intraperitoneal chemotherapy approaches may also improve outcomes in patients. Moreover, evolving immunotherapeutic opportunities could also positively impact patient outcomes. Here we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in ovarian cancer.
MIDER Authors
Citations
Altmetric:
Date
2022-12-15
Type
Article
Subject
Oncology. Pathology., Gynaecology
Collections
Citation
Algethami M, Kulkarni S, Sadiq MT, Tang HKC, Brownlie J, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S. Towards Personalized Management of Ovarian Cancer. Cancer Manag Res. 2022 Dec 15;14:3469-3483. doi: 10.2147/CMAR.S366681.
Journal / Source Title
Cancer Management and Research
DOI
10.2147/CMAR.S366681
PMID
36545222
Publisher
Taylor and Francis Group